Allergan is buying Motus Therapeutics, a subsidiary of Rhythm Holding designed to hold its diabetic gastroparesis treatment relamorelin, under an option deal…

ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.

DBV posts peanut allergy data, TiGenix looks to file for an IPO, Oasmia is buying a cancer drug and more.

In our EuroBiotech roundup this week, NeuroVive closes its Lyon subsidiary, ObsEva misses a primary endpoint, Active Biotech offloads a cancer drug, and more.

It has discontinued lead Phase IIb maturation inhibitor BMS-955176, which it bought from BMS, and COPD candidate losmapimod.

Biogen is aggressively pursuing neurodegenerative diseases, such as spinal muscular atrophy and Alzheimer’s disease.

Genomics Medicine Ireland has raised $40 million in a Series A round to create a genomic R&D program based in Dublin.

An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.

Verona Pharma has secured funding for a Phase IIa trial of its PDE3/PDE4 inhibitor RPL554 in cystic fibrosis patients.